ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
Novartis Pharmaceuticals · NCT07448610
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 2–100 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 4
- Target enrollment
- 36
- US sites recruiting
- 1
- Study start
- August 27, 2026
- Record last updated
- September 18, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).
Being studied: Onasemnogene Abeparvovec-brve
Conditions: Spinal Muscular Atrophy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Key Inclusion Criteria
A participant will be enrolled in STREAM only if all the following conditions are met:
- The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).
- He or she is ≥ 2 years of age on the day of the intrathecal injection.
- The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.
- One of the following functional categories applies at screening:
- independently ambulatory child/adolescent 2 - \<18 years; or
- independently ambulatory adult (≥ 18 years).
- non-ambulatory (includes walkers with assistance) adult > 18 years with entry level RULM at baseline
- At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.
Key Exclusion Criteria
A participant will be excluded if any of the following conditions apply:
- Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
- An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
- Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
- Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
- Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.
Other protocol inclusion, exclusion criteria may apply.
Recruiting US locations
Columbia University Medical Center
New York, NY 10032
Site contact: Claudia Chiriboga
Study contacts (from the official record)
- Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
- Novartis Pharmaceuticals